NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Amneal Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Amneal Pharmaceuticals develops, manufactures, and distributes essential medicines through three divisions. Affordable Medicines provides generic drugs, injectable products, and biosimilars. Specialty offers branded pharmaceuticals for central nervous system and endocrine conditions. AvKARE distributes pharmaceutical products to federal, retail, and institutional customers. The company operates in the United States, India, and Ireland.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Amneal Pharmaceuticals Inc stock.
Overvalued: intrinsic value $9.53 per share, market price $19.36, margin of safety -103.1% (as of 2026-10-19).
Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $9.53; the price of $19.36 is 103% above that value, and 74% of that value comes from beyond year five.
Leak Score: 45/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
23 more in this industry show a wider margin of safety.
AMRX is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $9.53; the price of $19.36 is 103% above that value, and 74% of that value comes from beyond year five.
$9.53 per share (as of the 2026-10-19 close), against a market price of $19.36. That is a margin of safety of -103.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
45 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.